Cell and Gene Therapy
Refine Search
Biotechnology
US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ahead with its cardiac gene therapy pipeline and fund operations into 2028. 28 May 2025
Biotechnology
German biotech TQ Therapeutics today announced the acquisition of Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Financial terms of the agreement were not disclosed. 28 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Biotechnology
The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has obtained regulatory approval from the domestic regulator for Elevidys Intravenous Infusion (delandistrogene moxeparvovec) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway. 15 May 2025
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Biotechnology
US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation. 8 May 2025
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has presented data from its Phase III LUMEOS study and disclosed that the trial did not meet its primary endpoint. 6 May 2025
Biotechnology
Some $45 million has been raised in a Series B financing round by Nuevocor, an IND-stage biotech developing therapies for genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects. 6 May 2025
Biotechnology
Portugal-based Hovione and Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences, today announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of hepatocellular carcinoma (HCC), a therapeutic indication developed by Firstgene. 6 May 2025
Biotechnology
Benchtop cell factory company Astraveus has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen). 6 May 2025
Biotechnology
T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. 5 May 2025
Biotechnology
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales projected to rise from $291 million in 2024 to $1.5 billion in 2030. 2 May 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Biotechnology
Galapagos has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a major step in the company’s planned division into two focused businesses. 22 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Biotechnology
US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ahead with its cardiac gene therapy pipeline and fund operations into 2028. 28 May 2025
Biotechnology
German biotech TQ Therapeutics today announced the acquisition of Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Financial terms of the agreement were not disclosed. 28 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Biotechnology
The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has obtained regulatory approval from the domestic regulator for Elevidys Intravenous Infusion (delandistrogene moxeparvovec) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway. 15 May 2025
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Biotechnology
US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation. 8 May 2025
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has presented data from its Phase III LUMEOS study and disclosed that the trial did not meet its primary endpoint. 6 May 2025
Biotechnology
Some $45 million has been raised in a Series B financing round by Nuevocor, an IND-stage biotech developing therapies for genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects. 6 May 2025
Biotechnology
Portugal-based Hovione and Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences, today announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of hepatocellular carcinoma (HCC), a therapeutic indication developed by Firstgene. 6 May 2025
Biotechnology
Benchtop cell factory company Astraveus has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen). 6 May 2025
Biotechnology
T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. 5 May 2025
Biotechnology
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales projected to rise from $291 million in 2024 to $1.5 billion in 2030. 2 May 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Biotechnology
Galapagos has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a major step in the company’s planned division into two focused businesses. 22 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze